Lung Tumor Clinical Medical Center in Shanghai Chest Hospital, Shanghai, China.
J Surg Oncol. 2013 Feb;107(2):167-72. doi: 10.1002/jso.23256. Epub 2012 Sep 20.
To evaluate long-term survival in thymic epithelial tumors (TETs), we present our experiences at a single institution in China.
We performed a retrospective analysis including 115 patients with TETs from 2001 to 2006. Histological diagnosis was completed based on the new WHO classification system. A univariate and multivariate survival analysis was performed, which included myasthenia gravis (MG), WHO histological type, Masaoka stage, completeness of resection, and adjuvant radiotherapy (RT).
WHO histological subtype was closely correlated with that of Masaoka stage. The overall median survival time was 84.4 months and the 7-year survival rate was 78%. In the univariate analysis, three prognostic factors, including WHO histology type, Masaoka stage and complete resection, were statistically significant. In the analysis of the cases with complete resection, adjuvant RT did not show obvious survival benefit. In the multivariate analysis, Masaoka stage was the only independent factor that predicted long-time survival.
Thymic carcinoma should be regarded as a different category of the disease due to its aggressive and poorer prognosis. Complete resection of the tumor and Masaoka stage I and II were found to contribute to a better survival. Adjuvant RT is not recommended for patients with complete resection in thymomas.
为了评估胸腺瘤（TET）的长期生存率，我们报告了我们在一家中国机构的经验。
我们对 2001 年至 2006 年间的 115 例 TET 患者进行了回顾性分析。根据新的 WHO 分类系统完成了组织学诊断。进行了单因素和多因素生存分析，包括重症肌无力（MG）、WHO 组织学类型、Masaoka 分期、切除的完整性和辅助放疗（RT）。
WHO 组织学亚型与 Masaoka 分期密切相关。总中位生存时间为 84.4 个月，7 年生存率为 78%。在单因素分析中，有三个预后因素，包括 WHO 组织学类型、Masaoka 分期和完全切除，具有统计学意义。在完全切除病例的分析中，辅助 RT 并没有显示出明显的生存获益。在多因素分析中，Masaoka 分期是唯一预测长期生存的独立因素。
胸腺癌应被视为一种不同类别的疾病，因其侵袭性和预后较差。肿瘤的完全切除和 I、II 期 Masaoka 分期有助于获得更好的生存。对于完全切除的胸腺瘤患者，不推荐辅助 RT。
